Citadel Advisors
PSTX

Citadel Advisors’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Citadel Advisors’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,700
Closed -$170K – 16022
2024
Q4 		$170K Sell
17,700
-30,600
-63% -$160K ﹤0.01% 10692
2024
Q3 		$138K Sell
48,300
-86,400
-64% -$267K ﹤0.01% 10676
2024
Q2 		$393K Buy
134,700
+41,700
+45% +$114K ﹤0.01% 8561
2024
Q1 		$297K Buy
+93,000
New +$310K ﹤0.01% 9474
2023
Q4 		– Sell
-21,200
Closed -$50.5K – 15457
2023
Q3 		$50.5K Sell
21,200
-26,700
-56% -$56K ﹤0.01% 11752
2023
Q2 		$84.3K Buy
47,900
+10,200
+27% +$26.1K ﹤0.01% 11180
2023
Q1 		$116K Buy
37,700
+12,300
+48% +$73.7K ﹤0.01% 11051
2022
Q4 		$135K Buy
25,400
+8,000
+46% +$36.6K ﹤0.01% 10776
2022
Q3 		$61K Buy
+17,400
New +$57.5K ﹤0.01% 11493
2022
Q2 		– Sell
-10,200
Closed -$46K – 14351
2022
Q1 		$46K Buy
+10,200
New +$46K ﹤0.01% 12850
2021
Q4 		– Sell
-11,300
Closed -$82K – 14973
2021
Q3 		$82K Buy
+11,300
New +$97K ﹤0.01% 13056
2021
Q2 		– Sell
-12,600
Closed -$120K – 14602
2021
Q1 		$120K Buy
+12,600
New +$124K ﹤0.01% 12300

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citadel Advisors's PSTX Position: Q1 2025 in Review

Citadel Advisors sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 154,764 shares — an estimated $1.49M sold.

Citadel Advisors first reported a position in PSTX in Q3 2020 and held it in 13 quarters. The position peaked at $1.49M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Citadel Advisors reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 154,764 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $1.49M.
  • Citadel Advisors first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 13 quarters.
  • Citadel Advisors's Poseida Therapeutics, Inc. Common Stock position peaked at $1.49M in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.